Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 7/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4993330 | 0.87 | CHEK1 (0.57) | CHEK1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL4994249 | 0.86 | CHEK1 (0.56) | CHEK1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL5003418 | 0.86 | CHEK1 (0.55) | CHEK1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL4991463 | 0.85 | CHEK1 (0.45) | CHEK1MAPTSMN1; SMN2LMNARXFP1 | |
| SCHEMBL4997072 | 0.84 | CHEK1 (0.54) | CHEK1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL5002996 | 0.84 | LMNA (0.49) | CHEK1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL4995485 | 0.83 | MAPT (0.50) | CHEK1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL4997341 | 0.83 | CHEK1 (0.43) | CHEK1MAPTRXFP1 | |
| SCHEMBL5003385 | 0.83 | CHEK1 (0.52) | CHEK1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL5003140 | 0.81 | PIM1 (0.47) | CHEK1MAPTSMN1; SMN2LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194574-A1 | Pyrazine Derivatives As Effective Compounds Against Infectious Diseases | AXXIMA PHARMACEUTICALS AG (DE) | 2008-08-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194574-A1 | Pyrazine Derivatives As Effective Compounds Against Infectious Diseases | PRNP, PSEN1, PPP5C | CHEK1 1668/4885MAPT 5/4885SMN1; SMN2 896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.